New drug made available to ALS patients unable to join trials
NCT ID NCT07088159
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This expanded access program offers the drug tazbentetol to adults with ALS who cannot join other clinical studies. Participants take one 300 mg pill by mouth each day. The program aims to check the drug's safety and whether it helps control the disease.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Tazbentetol (SPG302), a drug taken by mouth once daily
What this could lead to
If it works, this could provide a treatment option for ALS patients who cannot join other clinical trials.
What could go wrong
This is an expanded access program, not a formal trial, so results are limited. The drug's effectiveness and safety are still being studied, and it may not help everyone.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ALS (AMYOTROPHIC LATERAL SCLEROSIS) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Atlantic Health
AVAILABLESummit, New Jersey, 07901, United States
Contact Email: •••••@•••••
-
Baylor College of Medicine
AVAILABLEHouston, Texas, 77030, United States
Contact Email: •••••@•••••
-
California Pacific Medical Center
AVAILABLESan Francisco, California, 94109, United States
Contact Email: •••••@•••••
-
Cedar-Sinai Medical Center
AVAILABLELos Angeles, California, 90048, United States
Contact Email: •••••@•••••
-
Columbia University Medical Center
AVAILABLENew York, New York, 10032, United States
Contact Email: •••••@•••••
-
Dartmouth-Hitchcock Medical Center
AVAILABLELebanon, New Hampshire, 03756, United States
Contact Email: •••••@•••••
-
Kaiser Permanente Los Angeles
AVAILABLELos Angeles, California, 90027, United States
Contact Email: •••••@•••••
-
Mayo Scottsdale
AVAILABLEScottsdale, Arizona, 85259, United States
Contact Email: •••••@•••••
-
NYU Langone Health
AVAILABLENew York, New York, 10017, United States
Contact Email: •••••@•••••
-
New Mexico VA Health Care System
AVAILABLEAlbuquerque, New Mexico, 87108, United States
Contact Email: •••••@•••••
-
Nova Southeastern University
AVAILABLEDavie, Florida, 33314, United States
Contact Email: •••••@•••••
-
Synapticure
AVAILABLEChicago, Illinois, 60640, United States
Contact Email: •••••@•••••
-
Thomas Jefferson University
AVAILABLEPhiladelphia, Pennsylvania, 19107, United States
Contact Email: •••••@•••••
-
University of Alabama Birmingham
AVAILABLEBirmingham, Alabama, 35233, United States
Contact Email: •••••@•••••
-
VCU ALS Research Group
AVAILABLEHenrico, Virginia, 23233, United States
Contact Email: •••••@•••••